AI helps cardiologists track new drug’s effect on inflammation

Prof Nehal Mehta, our esteemed Scientific Advisory Board member and Director of Inflammatory Risk and Preventive Cardiology at the Hospital of the University of Pennsylvania spoke to Cardiovascular Business during ACC’2024.

“We are in an era of finding coronary disease, before we can see it…This (inflammation) is developing high-risk plaque (HRP), and HRP is something we know has a 5-fold risk of rupture in 5-years. Let’s stop heart attacks and let’s start understanding coronary inflammation,” shared Prof. Nehal Mehta, ???? He discussed the potential of CaRi-Heart FAI-Score and its application in tracking the impact of the new anti-inflammatory drug, orticumab. Watch his video interview here.